Delivering a new class of neuroprotective therapeutics by mining human oligodendrocyte biology

Pheno Therapeutics is an early stage biotechnology company (Edinburgh, UK) with a highly differentiated small molecule drug discovery platform built to deliver a new class of transformative, regenerative and neuroprotective therapeutics.

Our People

Our discovery engine was built on the pioneering research of our co founders, Professors Siddharthan Chandran and Neil Carragher (University of Edinburgh, UK). Financial backing has been provided by two leading life sciences investors.

Based in Edinburgh and positioned to deploy the University’s world-leading expertise in phenotypic screening, stem cell technology and myelin biology, we aim to discover and develop small molecule therapeutics that promote remyelination for a variety of unmet medical needs.
Our Platform
We aim to develop an effective remyelination therapeutic which can be added onto current immune modulator drugs to deliver neuroprotection leading to arrest or slowing down of neurological disease progression and long term disability.

Our visions is to mine and harness the power of human oligodendrocyte biology to deliver world leading neurotherapeutics that transform the lives of patients with disabling neurological disease.
Find Out More

Our Pipeline

Based in Edinburgh and positioned to deploy the University’s world-leading expertise in phenotypic screening, stem cell technology and myelin biology, we aim to discover and develop small molecule therapeutics that promote remyelination for the treatment of multiple sclerosis.

Pheno Therapeutics aims to identify novel remyelinating agents and develop transformational therapeutics that enhance the repair of damaged myelin sheaths.
Find Out More

Latest News

Find out more about us

Find out more about Pheno Therapeutics and the ground breaking work we do.

Pheno Therapeutics

Based in Edinburgh and positioned to deploy the University’s world-leading expertise in phenotypic screening, stem cell technology and myelin biology, we aim to discover and develop small molecule therapeutics that promote remyelination for the treatment of multiple sclerosis.
Copyright © 2024 All Rights Reserved
| Made by FDM Digital with ❤️
crossmenu